Association Between Colitis and Immune Checkpoint Inhibitor Use: Analysis of the FDA Adverse Event Reporting System (FAERS)

被引：0
|
作者：
Tunio, Nahel A. [1 ]
Cooper, Gregory S. [1 ]
机构：
[1] Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2019年 / 114卷
关键词：
D O I：
10.14309/01.ajg.0000590048.19557.62
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
129
引用
收藏
页码：S76 / S77
页数：2
相关论文
共 50 条
  • [21] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [22] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [23] Melanoma associated with TNFa inhibitor agents in the FDA Adverse Event Reporting System (FAERS): Analysis of reported outcomes
    Nardone, Beatrice
    Bhattacharya, Tanya
    Bruins, Finola M.
    Hammel, Josh A.
    Haugh, Isabel M.
    West, Dennis P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB209 - AB209
  • [24] The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS)
    Morris, Robert
    Todd, Megan
    Aponte, Nicole Zapata
    Salcedo, Milagros
    Bruckner, Matthew
    Garcia, Alfredo Suarez
    Webb, Rachel
    Bu, Kun
    Han, Weiru
    Cheng, Feng
    JOURNAL OF CARDIOVASCULAR AGING, 2023, 3 (04):
  • [25] Carfiilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
    Buck, Benjamin
    Kellett, Eric
    Addison, Daniel
    Vallakati, Ajay
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (03) : 134 - 141
  • [26] Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
    Timbrook, Tristan T.
    McKay, Lydia
    Sutton, Jesse D.
    Spivak, Emily S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [27] Immune checkpoint Inhibitor related myocarditis reported through the FDA adverse event reporting system: pharmacovigilance trends in reporting and outcomes
    Reeves, David J.
    Leffers, Kevin
    Rao, Vijay U.
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [28] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    HELIYON, 2024, 10 (14)
  • [29] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [30] ADVERSE EVENTS ASSOCIATED WITH ANTIOBESITY MEDICATION USE: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM FAERS 1997-2015
    Yue, X.
    Xia, Y.
    Guo, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A241 - A241
12345